[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoporosis-in-post-menopausal-women\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoporosis-in-post-menopausal-women":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100613494","bone-health-in-postmenopausal-women-the-effect-of-exercise-with-or-without-medication-for-osteoporosis-100613494",false,"NCT07267325","Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis","The Effect of Exercise With or Without Antiresorptive Therapy, on Bone Properties in Postmenopausal Women With Low BMD - Randomised Controlled Unilateral Intervention Trial","BEAT-OP","Inclusion Criteria:\n\n* Women aged 55-75 years old\n* \\>4y since menopause\u002Fhysterectomy\u002Foophorectomy.\n* Baseline femoral neck or lumber spine BMD T-score between -1 and -3.\n* Able to complete the hopping exercises.\n* Have no regular involvement for more than once\u002Fweek in:\n\n  1. Strength, powerlifting or high load resistance exercise.\n  2. High to moderate impact exercise that known to involve ground reaction forces 2 to 4 times greater than body weight (e.g. Jogging).\n* Treatment group: taking antiresorptive treatment for osteoporosis continuously for at least 12 months, and who intend to continue this medication for the rest of the study.\n* Control group: not taking any medication affecting bone and no intention to commence such medication for the rest of the study.\n\nExclusion Criteria:\n\n* Body mass index (BMI) \\>35 kg\u002Fm2\n* Any medical condition, surgery, or injuries that contraindicate exercises including lower limb or back pain, knee or hip osteoarthritis.\n* Vertebral fracture or multiple low trauma fractures (recent expert consensus recommends lower impact exercise for these groups)\n* Replacement of hip joint(s)",true,"FEMALE","55 Years","75 Years",{"count":22,"type":23},110,"ESTIMATED","INTERVENTIONAL",[26],"NA","Osteoporosis is a systemic bone disorder characterised by a reduced bone mass and structural deterioration, increasing the risk of fragility fractures, particularly in women post-menopause. Bone mass and structure can be assessed by scans.\n\nAntiresorptive medications are commonly prescribed to reduce bone resorption, preventing further bone loss and thus reducing the possibility of fracture. Exercise can also benefit bone mass and structure but current evidence do not show whether exercise is more, or less, effective in combination with antiresorptive medication.\n\nThis study will compare the effect of a brief, home-based exercise programme on bone mineral and structural properties in women taking\u002F not taking antiresorptive medication.",[29],"Osteoporosis in Post-menopausal Women",[31,32,33,34,35,36,37],"Exercise","Bone mineral density","Bone strength","Bone geometry","Fracture risk","Bone structure","Biomarkers","NOT_YET_RECRUITING","2025-12-04",{"date":41,"type":42},"2025-12-05","ACTUAL",{"date":44,"type":23},"2026-01-01",{"date":46,"type":23},"2027-09",{"name":48,"class":49},"Loughborough University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100582501","phase-4-a-clinical-study-on-the-effect-of-discontinuing-alendronate-in-postmenopausal-women-with-osteoporosis-after-a-treatment-period-without-fractures-100582501","NCT06864130","A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","The Alendronate Discontinuation Study","ALEXIS","Inclusion Criteria:\n\n* Female\n* Postmenopausal\n* Current treatment with Alendronate\n* Alendronate treatment \\>3 år AND no fracture OR\n* Alendronate treatment \\>5 år AND latest low energy fracture \\> 3 years ago\n\nExclusion Criteria:\n\n* T-score \\\u003C - 3,5 in hip (total hip or femoral neck) or lumbar spine\n* Treatment with systemic glucocorticoids, ongoing or within 12 months\n* Uncontrolled inflammatory disease\n* Active malignancy\n* eGFR \\\u003C 40 mL\u002Fmin\n* Atypical femur fracture (ever)\n* OsteoNecrosis of the Jaw (active)\n* Unable to give inform consent",{"count":60,"type":23},1400,[62],"PHASE4","The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:\n\n* What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk.\n* Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss.\n\nResearchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.\n\nParticipants will:\n\n* Either take alendronate once weekly for three years OR discontinue their treatment\n* Visit the clinic at 6 and 18 months for blood samples\n* Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.",[29],[66,67,68,32,69],"Alendronate","Discontinuation","Osteoporosis","post-menopausal","RECRUITING","2025-02-28",{"date":73,"type":42},"2025-03-07",{"date":75,"type":42},"2025-02-21",{"date":77,"type":23},"2029-09-15",{"name":79,"class":49},"Odense University Hospital",7,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100571445","phase-4-efficacy-of-romosozumab-and-denosumab-combined-treatment-in-postmenopausal-osteoporosis-patients-with-multiple-fragility-fractures-100571445","NCT06720350","Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures","MORD","Inclusion Criteria:\n\n* Postmenopausal Women\n* Patients with Osteoporosis\n* Patients aged between 55 and 85 years old\n\nExclusion Criteria:\n\n* Patient with history of Serebrovascular diseases\n* Patient with history of Miyocardial Infarction\n* Patients who have calcium metabiolism disturbances\n* Patients with chronic kidney diseases\n* Patient with history of allergic reactions to denosumab or romosozumab","85 Years",{"count":90,"type":23},60,[62],"The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is under at least 2 years of denosumab treatment. The main questions aimed to answer are:\n\n* Does it effective to prevent fractures add Romosozumab to ongoing denosumab treatment?\n* If it is appropiate to quit denosumab for starting 1 year romosozumab treatment?\n* If there is complications in denosumab and romosozumab combination treatment?\n\nResearchers will compare the Romosozumab 210mg subcutaneous(sc) monthly plus denosumab 60mg per 6 months sc treatment to prooceeding denosumab treatment and romosozumab 210mg monthly treatment in patient whom denosumab cessaced.\n\nParticipians are postmenopousal women with osteoporosis and they are under at least 2 years of treatment with denosumab and they will:\n\n* Add 210 mg monthly romosozumab sc injection or switch to 210 mg monthly romosozumab sc injection or proceed 60mg per 6 months denosumab sc injection\n* Visit the clinic at least once every 3 months and first month of new treatment regimen, blood tests per 3 months and Bone mineral density examination per 6 months\n* Keep a diary of their symptoms",[29],[68,95,96,97],"Combination Therapy","Romosozumab","Denosumab","2024-12-25",{"date":100,"type":42},"2024-12-27",{"date":102,"type":23},"2025-01-15",{"date":104,"type":23},"2026-12-15",{"name":106,"class":49},"Marmara University"]